Thirty FDA warning letters and a Hims & Hers deal shift the compounded semaglutide market
The March 2026 enforcement wave narrows where compounded semaglutide can legally come from, which matters to patients who relied on its lower price.
Federal enforcement against sellers of compounded GLP-1 drugs reached a new level in March 2026, when the FDA released a set of thirty warning letters and Novo Nordisk ended its dispute with one of the biggest telehealth platforms selling compounded semaglutide.
The letters went out on February 20, 2026 and became public on March 3, addressed to telehealth companies and online wellness clinics [2]. They cite two sections of the Federal Food, Drug, and Cosmetic Act, 502(a) and 502(bb), which bar false or misleading labeling and advertising [2]. The signer was Matthew J. Lash, acting director of the Office of Compounding Quality and Compliance at the FDA's Center for Drug Evaluation and Research [2]. Each recipient has fifteen working days to tell the agency's Office of Compliance what it has fixed, including which compounder supplied the drug, what the labels say, and which website claims were pulled. Companies that stay silent could face seizure of products or a court injunction, the letters warn [2].
Regulators objected to how some sellers described their products. According to the FDA, many implied that a compounded drug was the same as, or could stand in for, an FDA-approved brand, for instance by claiming "the same ingredients" or saying the product had been "tested in clinical trials" [2]. Other letters faulted companies for obscuring that a drug was compounded or for not disclosing where it came from [2].
Six days after the letters became public, Novo Nordisk and Hims & Hers said they had settled. Hims & Hers will offer Novo Nordisk's branded semaglutide, Ozempic and Wegovy, through its platform and will stop advertising and marketing compounded GLP-1 drugs except where a patient's medical need calls for it [2]. Novo Nordisk withdrew its patent infringement lawsuit against the company while keeping the right to refile [2]. FDA Commissioner Marty Makary endorsed the arrangement. Announcing the letters, he said, "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action." Compounded drugs can matter for shortages or unusual patient needs, he said, but compounders should not compound "in a way that circumvents FDA's approval process" [2].
The accounts of that month do not match on every point. One describes a coordinated March sweep of more than fifty warning letters to telehealth firms and compounding pharmacies, called the largest such action against GLP-1 compounders in U.S. history [1]. The other counts thirty letters released March 3 [2]. The two figures have not been reconciled in public. The accounts also describe Hims & Hers differently: one says the company dropped compounded semaglutide entirely, as did Ro, after enforcement attention and a Justice Department referral in early 2026 [1]; the other frames the change as ending compounded marketing except where medically necessary while selling branded semaglutide [2].
March did not come out of nowhere. After the FDA declared the semaglutide shortage over in February 2025, it set shutdown dates of April 22, 2025 for 503A state-licensed pharmacies and May 22, 2025 for 503B outsourcing facilities, covering products that were "essentially a copy" of semaglutide [1]. Injunctions won by industry groups shielded some 503B operators for a time in mid-2025 [1]. In September 2025 the agency sent roughly 100 cease-and-desist letters over deceptive direct-to-consumer advertising, and a warning letter that month went to Hims & Hers [1][2]. A February 20, 2026 letter went to Join Josie over false or misleading claims [1].
The crackdown has critics. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, said he was "puzzled" by the commissioner's framing and noted that under Supreme Court precedent, lawful pharmacies cannot be broadly barred from sharing truthful information about their services [2]. The Court's 2002 ruling in Thompson v. Western States Medical Center limited how far the government may restrict compounding pharmacy advertising [2].
Why it matters for patients
Cost sits at the center of this for many people. Compounded semaglutide has generally run $150 to $400 a month, while brand-name Ozempic or Wegovy costs $935 to $1,349 a month without insurance [1]. As large-scale compounding shrinks, patients who built a budget around the lower figure may have to find another source, sometimes mid-treatment.
Safety data gathered during the compounding boom helps explain the scrutiny. By April 30, 2025, the FDA had received 520 adverse event reports tied to compounded semaglutide [1]. A common one involved people injecting 5 to 20 times the intended dose after mixing up units and mg/mL concentrations, a hazard that comes with multi-dose vials rather than fixed-dose pens [1]. Only semaglutide base is FDA-approved; semaglutide sodium and semaglutide acetate are unapproved salt forms that have not been checked for safety or effectiveness [1].
One route is still open. On April 30, 2026, the FDA proposed taking semaglutide and tirzepatide off the 503B Bulk Drug Substances List, which would end large-batch production without individual prescriptions [1]. Compounding one prescription at a time under Section 503A, through a state-licensed pharmacy, remains possible when a prescriber documents a clinical reason: an allergy to an inactive ingredient in Ozempic, Wegovy or Rybelsus, a dosage form that is not sold commercially, or a dose that no approved strength provides [1]. Price alone does not count [1].
What happens next
Comments on the proposed 503B removal are open through June 29, 2026, and the rule is widely expected to be finished in the third quarter of 2026 [1]. The FDA's April 1, 2026 clarification of its compounding policies does not carry the force of law but signals its enforcement plans [1]. Companies that received the February letters have fifteen working days to respond [2]. Whether other telehealth companies copy the Hims & Hers arrangement has not been disclosed [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.